Volume 27, Number 1—January 2021
Research Letter
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Table 2
Laboratory, electrocardiographic and clinical monitoring data for patient treated for XDR TB, United States*
Date | AST, IU/L | ALT, IU/L | ALP, IU/L | Creatinine, mg/dL | Magnesium, mg/dL | Hgb, g/dL | Leukocyte, × 109/L | Plt, × 109/L | QTc, msec | Notes |
---|---|---|---|---|---|---|---|---|---|---|
Initial treatment with rifampin, isoniazid, pyrazinamide, and ethambutol | ||||||||||
2019 Aug 2 |
67 |
86 |
221 |
0.66 |
NT |
10.4 |
3.97 |
272 |
NT |
None |
Bridging regimen of bedaquiline, linezolid, moxifloxacin, cycloserine, clofazimine, and ethambutol | ||||||||||
2019 Oct 3 | 53 | 62 | 121 | 0.64 | 1.9 | 12.7 | 5.4 | 278 | 402 | None |
2019 Oct 15 |
73 |
70 |
147 |
NT |
NT |
12.6 |
5.3 |
243 |
NT |
None |
BPaL regimen | ||||||||||
2019 Oct 21 | 57 | 71 | 135 | 0.94 | 1.9 | 12.9 | 3.9 | 257 | 413 | None |
2019 Nov 11 | 40 | 53 | 113 | 1.01 | 1.9 | 12.3 | 4.9 | 237 | 426 | Pantoprazole started for brief nausea |
2019 Dec 2 | 52 | 63 | 118 | 0.77 | 1.9 | 10.7 | 4.3 | 289 | 421 | None |
2019 Dec 16 | NT | NT | NT | NT | NT | 11.2 | 4.7 | 267 | NT | None |
2020 Jan 6 | 58 | 74 | 107 | 0.80 | 2.0 | 12.5 | 5.1 | 271 | 422 | None |
2020 Feb 3 | 36 | 39 | 89 | 0.76 | 1.9 | 12.2 | 4.2 | 258 | 429 | None |
*Initial treatment period was August 5–September 9, 2019; bridging regimen period October 7–21, 2019; BPaL treatment period October 21, 2019–April 21, 2020. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BPaL, bedaquiline, pretomanid, and linezolid; Hgb, hemoglobin; leukocyte, leukocyte count; NT, not tested; Plt, platelet; QTc, corrected QT interval.